REVENUE

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Revenue

REVENUE

The following table summarizes the disaggregation of revenue by nature:

	Three Months Ended March 31,
Dollars in millions	2023		2022
Net product sales	$	11,048	$	11,308
Alliance revenues	144		188
Other revenues	145		152
Total Revenues	$	11,337	$	11,648

The following table summarizes GTN adjustments:

	Three Months Ended March 31,
Dollars in millions	2023		2022
Gross product sales	$	17,288	$	16,650
GTN adjustments (a)
Charge-backs and cash discounts	(2,091)		(1,763)
Medicaid and Medicare rebates	(2,482)		(2,084)
Other rebates, returns, discounts and adjustments	(1,667)		(1,495)
Total GTN adjustments	(6,240)		(5,342)
Net product sales	$	11,048	$	11,308

(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $87 million and $74 million for the three months ended March 31, 2023, and 2022, respectively.

The following table summarizes the disaggregation of revenue by product and region:

	Three Months Ended March 31,
Dollars in millions	2023		2022
In-Line Products
Eliquis	$	3,423	$	3,211
Opdivo	2,202		1,923
Pomalyst/Imnovid	832		826
Orencia	764		792
Sprycel	429		483
Yervoy	508		515
Mature and other products	467		537
Total In-Line Products	8,625		8,287
New Product Portfolio
Reblozyl	206		156
Abecma	147		67
Opdualag	117		6
Zeposia	78		36
Breyanzi	71		44
Onureg	34		23
Inrebic	25		18
Camzyos	29		—
Sotyktu	16		—
Total New Product Portfolio	723		350
Total In-Line Products and New Product Portfolio	9,348		8,637
Recent LOE Products(a)
Revlimid	1,750		2,797
Abraxane	239		214
Total Recent LOE Products	1,989		3,011
Total revenues	$	11,337	$	11,648
United States	$	8,033	$	7,694
International	3,149		3,727
Other(b)	155		227
Total revenues	$	11,337	$	11,648

(a)    Recent LOE Products include products with significant decline in revenue from the prior reporting period as a result of a loss of exclusivity.

(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $166 million and $147 million for the three months ended March 31, 2023 and 2022, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales.